Page 5 - Keith Berman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DOJ and SEC Pursue Decision Diagnostics CEO on COVID-19 Testing Fraud Posted on 12/19/2020 The U.S. Justice Department revealed that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 test. The false claim led to investor losses. Keith Berman, 67, the CEO of Decision Diagnostics Inc., was charged with one count of securities fraud and one count of making false statements, the DOJ said. The SEC temporarily suspended trading in Decision Diagnostics’ securities on April 23, 2020. The complaint...

SEC Charges Biotech Company and CEO with Fraud Concerning COVID-19 Blood Testing Device Washington, D.C.--(Newsfile Corp. - December 18, 2020) - The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 20...

SEC Lawsuit Alleges Biotech Firm, CEO Misled Investors About COVID-19 Tests The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp. and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute. In a complaint filed on Thursday in Manhattan federal court, the SEC said Chief Executive Keith Berman made materially false statements between March and June about what he claimed was his company’s blood testing kit, and its efforts to obt...

CEO of medical device company charged in COVID-19 related fraud scheme 4 Shares The chief executive officer of a California-based medical device company was indicted by a federal grand jury in connection with an alleged scheme to defraud investors by making false and misleading statements about the purported development of a new COVID-19 test, leading to millions of dollars in investor losses.  Keith Berman, 67, the CEO of Decision Diagnostics Inc. was charged by indictment with one count of securities fraud and one count of making false statements.  The indictment alleges that, from Februa...

FOR IMMEDIATE RELEASE Washington D.C., Dec. 18, 2020 — The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 2020. The SEC's complaint alleges that Decision Diagnostics and Berman ...